226 related articles for article (PubMed ID: 22799029)
41. Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
Totaro KA; Barthelme D; Simpson PT; Jiang X; Lin G; Nathan CF; Sauer RT; Sello JK
ACS Infect Dis; 2017 Feb; 3(2):176-181. PubMed ID: 28183185
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
43. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
44. Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs.
Henriques de Jesus CS; Chiorcea-Paquim AM; Barsan MM; Diculescu VC
Talanta; 2019 Jul; 199():32-39. PubMed ID: 30952265
[TBL] [Abstract][Full Text] [Related]
45. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
[TBL] [Abstract][Full Text] [Related]
46. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor.
Hasegawa M; Yasuda Y; Tanaka M; Nakata K; Umeda E; Wang Y; Watanabe C; Uetake S; Kunoh T; Shionyu M; Sasaki R; Shiina I; Mizukami T
Eur J Med Chem; 2014 Jan; 71():290-305. PubMed ID: 24321833
[TBL] [Abstract][Full Text] [Related]
47. Proteasome inhibitors; synthesis and activity of arecoline oxide tripeptide derivatives.
Marastoni M; McDonald J; Baldisserotto A; Canella A; De Risi C; Pollini GP; Tomatis R
Bioorg Med Chem Lett; 2004 Apr; 14(8):1965-8. PubMed ID: 15050638
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and biological evaluation of dipeptides as novel non-covalent 20S proteasome inhibitors.
Yang YJ; Wang K; Yang Y; Lai FF; Chen XG; Xiao ZY
J Asian Nat Prod Res; 2021 May; 23(5):436-451. PubMed ID: 33844614
[TBL] [Abstract][Full Text] [Related]
49. Application of two direct C(sp3)-H functionalizations for total synthesis of (+)-lactacystin.
Yoshioka S; Nagatomo M; Inoue M
Org Lett; 2015 Jan; 17(1):90-3. PubMed ID: 25526222
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors.
Uysal S; Soyer Z; Saylam M; Tarikogullari AH; Yilmaz S; Kirmizibayrak PB
Eur J Med Chem; 2021 Jan; 209():112890. PubMed ID: 33039723
[TBL] [Abstract][Full Text] [Related]
51. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
[TBL] [Abstract][Full Text] [Related]
52. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.
McCormack TA; Cruikshank AA; Grenier L; Melandri FD; Nunes SL; Plamondon L; Stein RL; Dick LR
Biochemistry; 1998 May; 37(21):7792-800. PubMed ID: 9601040
[TBL] [Abstract][Full Text] [Related]
53. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.
Carmony K; Lee W; Kim KB
Chembiochem; 2016 Nov; 17(22):2115-2117. PubMed ID: 27605113
[TBL] [Abstract][Full Text] [Related]
54. Development of novel proteasome inhibitors based on phthalazinone scaffold.
Yang L; Wang W; Sun Q; Xu F; Niu Y; Wang C; Liang L; Xu P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2801-2805. PubMed ID: 27158142
[TBL] [Abstract][Full Text] [Related]
55. Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.
Maurits E; Degeling CG; Kisselev AF; Florea BI; Overkleeft HS
Chembiochem; 2020 Nov; 21(22):3220-3224. PubMed ID: 32598532
[TBL] [Abstract][Full Text] [Related]
56. Secondary Metabolites Produced by an Endophytic Fungus Pestalotiopsis sydowiana and Their 20S Proteasome Inhibitory Activities.
Xia X; Kim S; Liu C; Shim SH
Molecules; 2016 Jul; 21(7):. PubMed ID: 27447600
[TBL] [Abstract][Full Text] [Related]
57. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
58. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
59. Novel 5-substituted 1H-tetrazoles as cyclooxygenase-2 (COX-2) inhibitors.
Al-Hourani BJ; Sharma SK; Suresh M; Wuest F
Bioorg Med Chem Lett; 2012 Mar; 22(6):2235-8. PubMed ID: 22341941
[TBL] [Abstract][Full Text] [Related]
60. 1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome.
Maréchal X; Genin E; Qin L; Sperandio O; Montes M; Basse N; Richy N; Miteva MA; Reboud-Ravaux M; Vidal J; Villoutreix BO
Curr Med Chem; 2013; 20(18):2351-62. PubMed ID: 23531222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
